文献速递甲状腺疾病

BRAF诱导的EHF表达影响侵袭性甲状腺乳头状癌中的TERT

BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究分析癌症基因组图谱中399例及本中心93例甲状腺乳头状癌(PTC)的ETS转录因子表达,发现EHF与不良临床特征、BRAFV600E及TERT启动子突变/表达相关,且BRAFV600E、TERT启动子突变与EHF高表达并存者无病生存期最短。体外实验提示BRAF诱导EHF上调,进而增加TERT启动子突变细胞的TERT表达。

要点

  • 在PTC两个队列中,EHF表达与不良临床特征、BRAFV600E及TERT启动子突变/表达一致相关。
  • BRAFV600E突变PTC中,EHF高表达与较短无病生存期相关;BRAFV600E、TERT启动子突变与EHF高表达并存者无病生存期最短。
  • 体外实验提示BRAF诱导EHF上调,EHF可能结合TERT启动子突变细胞并增加TERT表达。

核心结论

  • ETS转录因子EHF与PTC不良预后相关,可能由BRAF诱导EHF上调、进而增加TERT启动子突变细胞的TERT表达所介导。

研究设计与样本

  • 分析癌症基因组图谱PTC队列(n=399)中28个ETS转录因子的转录组数据,并在本中心队列(n=93)中验证。
  • 进行体外实验,探讨BRAFV600E与TERT表达相关的调控作用。

主要发现

  • 癌症基因组图谱分析发现ETS1、ERG、FLI1、GABPA、EHF、ETV6和SPDEF在I+II期与III+IV期之间差异表达。
  • 在两个队列中,EHF均与不良临床特征、BRAFV600E及TERT启动子突变/表达相关。
  • 在BRAFV600E突变PTC中,EHF高表达与较短无病生存期相关;BRAFV600E、TERT启动子突变与EHF高表达并存者无病生存期最短。
  • 在同时携带BRAFV600E和TERT启动子突变的细胞中,过表达EHF显著增加TERT表达,而敲低或药理抑制BRAF显著降低EHF和TERT表达。
  • 染色质免疫沉淀和定量PCR分析提示EHF在TERT启动子突变细胞中可能结合,而在TERT启动子野生型细胞中未结合。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma (PTC) have a synergistic effect on prognosis. This effect is believed to arise from MAPK activation triggered by BRAFV600E, leading to the upregulation of ETS transcription factors that bind to the mutant TERT promoter. OBJECTIVES: To explore the role of ETS factors in relation to clinical features, BRAFV600E, and TERT promoter mutations in PTC. DESIGN: Transcriptomic data for 28 ETS factors were analyzed in the PTC cohort of The Cancer Genome Atlas (n = 399) and subsequently validated in a local cohort (n = 93). In vitro experiments were performed to investigate the regulatory role in relation to BRAFV600E and TERT expression. RESULTS: The Cancer Genome Atlas identified ETS1, ERG, FLI1, GABPA, EHF, ETV6, and SPDEF as differentially expressed genes between stages I + II and III + IV. In both cohorts, EHF was consistently associated with adverse clinical features, BRAFV600E and TERT promoter mutation/expression. Notably, in BRAFV600E mutated PTC, high EHF expression was associated with shorter disease-free survival. Cases harboring concurrent BRAFV600E, TERT promoter mutations, and high EHF expression exhibited the shortest disease-free survival. In cells harboring concurrent BRAFV600E and TERT promoter mutation, overexpression of EHF significantly increased TERT expression, whereas knockdown or pharmacological inhibition of BRAF significantly decreased both EHF and TERT expression. In addition, chromatin immunoprecipitation and quantitative PCR analysis suggested a potential binding of EHF in TERT promoter mutant cells but not in TERT promoter wild-type cells. CONCLUSION: The ETS transcription factor EHF is associated with poor prognosis in PTC. This is potentially mediated by BRAF-induced upregulation of EHF, which in turn increases TERT expression in TERT promoter mutated cells.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Xu Y, Gao J, Wang N, et al. BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39183149. doi:10.1210/clinem/dgae589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。